"10.1371_journal.pone.0077050","plos one","2013-10-10T00:00:00Z","Alexandra Aronin; Shira Amsili; Tatyana B Prigozhina; Kobi Tzdaka; Jacob Rachmilewitz; Noam Shani; Mark L Tykocinski; Michal Dranitzki Elhalel","Nephrology and Hypertension Services, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; KAHR Medical LTD, Jerusalem, Israel; Office of the Dean, Jefferson Medical College, Philadelphia, Pennsylvania, United States of America","Conceived and designed the experiments: AA MDE. Performed the experiments: AA TP SA KT. Analyzed the data: AA TP SA. Contributed reagents/materials/analysis tools: NS. Wrote the manuscript: AA JR MLT SA MDE.","MDE has a research grant and consulting fee from KAHR Medical LTD. SA is employed by KAHR Medical LTD, NS CEO of KAHR Medical LTD, and MLT is a share holder and inventor - KAHR Medical LTD. F n14-TRAIL is a fusion protein protected by patents issued and licensed to KAHR medical, MLT is an inventor. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","10","Alexandra Aronin","AA",8,TRUE,2,4,3,5,TRUE,TRUE,FALSE,0,NA,FALSE
